Ingredients4-Dehydroepiandrosterone (4-DHEA) is a steroid that is an isomer of 5-dehydroepiandrosterone. The compound shares the same molecular formula and gross steroid backbone as the far more extensively studied 5-DHEA (prasterone/androstenolone), but differs in the position of its double bond within the steroid ring system. A positional isomer of prasterone (5-DHEA) which may have similar biological activity is 4-dehydroepiandrosterone (4-DHEA).
Systematic and common names include: 4-Dehydroepiandrosterone (4-DHEA); synonyms include 3β-hydroxy-4-androsten-17-one, 3β-hydroxyandrost-4-en-17-one, 3β-hydroxy-D4-androsten-17-one, 3β-hydroxy-etioallocholan-4-en-17-one, and 4-androsten-3β-ol-17-one. In the sports supplement and bodybuilding community, the compound is also marketed under the names 4-Andro, 4-Androsterone, and 4-Androstenolone.
4-Androstenolone is a naturally occurring DHEA isomer. Its structure closely resembles regular DHEA but the double bond is in the 4th position, which dramatically changes its effects. While conventional DHEA (5-DHEA) has its double bond between carbons 5 and 6, 4-DHEA has it between carbons 4 and 5 — a structural shift that places it directly on the classical Δ4 steroid pathway and affects its metabolic conversion routes.
A number of naturally occurring isomers of DHEA exist and may have similar activities. Some isomers of DHEA are 1-dehydroepiandrosterone (1-androsterone) and 4-dehydroepiandrosterone.
Dehydroepiandrosterone (DHEA), in its conventional 5-DHEA form, is an endogenous steroid hormone precursor and one of the most abundant circulating steroids in humans. It is produced in the adrenal glands, the gonads, and the brain, and functions as a metabolic intermediate in the biosynthesis of the androgen and estrogen sex steroids both in the gonads and in various other tissues. The 4-isomer (4-DHEA) exists endogenously as a minor steroid within the human steroidogenic cascade; it appears in the metabolic conversion of DHEA to androstenedione. DHEA and androstenediol can both be converted into their corresponding Δ4 products by hydroxysteroid dehydrogenases isoform 3B2, yielding 4-androstenedione (A4) and testosterone, respectively, placing 4-DHEA at a crossroads of the delta-4 steroid pathway.
As a dietary supplement, 4-DHEA is manufactured synthetically in a laboratory setting. It is sold primarily in oral tablet and capsule forms, often utilizing enhanced-delivery technologies. Commercially available preparations include non-methylated prohormone tablets containing 3β-hydroxy-androst-4-ene-17-one, often delivered via liposome tablet technology for improved absorption; these products are designed for cycled use. Some manufacturers use proprietary encapsulation systems combining phosphatidylcholine and hydroxypropyl beta-cyclodextrin (HPβCD) to attempt to improve oral bioavailability, addressing the known problem of low conversion rates with standard oral delivery. The compound is also available in sublingual and transdermal preparations, though peer-reviewed data specifically on 4-DHEA in these forms are absent.
DHEA broadly was marketed as a "fountain of youth," "super hormone," "antidote for aging," or "mother of hormones," and quickly introduced by the pharmaceutical industry in the 1980s despite a lack of solid research supporting its benefits, with no large human studies until the 1990s. It was later banned as an over-the-counter product in 1985 by the FDA due to its lack of evidence of safety and efficacy, and was later approved by the Dietary Supplement Health and Education Act as a dietary supplement in 1994.
The FDA banned over-the-counter sales of DHEA in 1985; however, since the passage of the Dietary Supplement Health and Education Act of 1994, DHEA has been widely available and marketed as a dietary supplement. The regulatory reinstatement under DSHEA (1994) applied to DHEA and its naturally occurring isomers — including 4-DHEA — provided these compounds are marketed as dietary supplements and not as drugs.
The compound is widely available in health food stores in the US, where it is marketed as a dietary supplement. However, the quality of DHEA and the wide variety of content is somewhat poorly regulated.
4-Androstenedione is a prohormone and intermediate in the biosynthesis of estrogens (i.e., estradiol and estrone) and testosterone from dehydroepiandrosterone (DHEA). Prior to the 2004 Anabolic Steroid Act, 4-androstenedione was marketed as a performance-enhancing dietary supplement. The passage of the Anabolic Steroid Control Act of 2004 in the United States scheduled androstenedione and numerous related prohormones as controlled substances. 4-DHEA subsequently emerged in the commercial market as a structurally distinct compound — an isomer of DHEA itself rather than a direct androstenedione analogue — and was positioned by some manufacturers as a legal alternative. The distinction is relevant: 4-DHEA, while certainly bringing about results in users and having its place, is NOT the same as what was historically called 4-AD. 4-DHEA is a two-step conversion to testosterone, not one.
4-DHEA specifically has no documented traditional or ethnobotanical history of use. There are no records of its isolation, identification, or intentional therapeutic use prior to the modern era of steroid chemistry. Its commercial emergence as a named supplement is a phenomenon of the early-to-mid 2010s, following regulatory changes that eliminated most first-generation prohormones. Any claimed "traditional use" references in the supplement marketplace conflate 4-DHEA with the broader history of conventional (5-DHEA) supplementation.
The broader DHEA family's historical use context is as follows: Initially considered an inert compound, interest in DHEA began to grow in the 1960s when it was found that DHEA-S is the most abundant steroid hormone in human plasma and that its levels decline with age. This age-decline observation sparked decades of research into supplementation for aging-related conditions, but this research pertains almost entirely to conventional 5-DHEA, not to the 4-isomer.
4-DHEA itself is not the ultimate bioactive agent; its pharmacological effects are attributed to its downstream conversion products. 4-DHEA requires a two-step conversion process involving 3β-HSD and 17β-HSD to convert it to both androstenedione and androstenediol respectively, and then to testosterone.
More specifically, the enzymatic pathway proceeds as follows: Step 1 converts 3β-hydroxy-androst-4-ene-17-one to androstenedione via 3β-hydroxysteroid dehydrogenase (3β-HSD); Step 2 converts androstenedione to testosterone via 17β-hydroxysteroid dehydrogenase (17β-HSD). Both conversion enzymes are naturally present in human tissue.
Androstenedione (4-androstenedione, Δ4-dione), also known as androst-4-ene-3,17-dione, is an endogenous weak androgen steroid hormone and intermediate in the biosynthesis of estrone and of testosterone from dehydroepiandrosterone (DHEA). Androstenedione is then converted to either testosterone or estrone: conversion to testosterone requires the enzyme 17β-hydroxysteroid dehydrogenase, while conversion to estrone requires the enzyme aromatase.
Most DHEA is sulfated, and part of DHEA is converted into androstenediol by AKR1C3. Additional DHEA and androstenediol can both be converted into their corresponding Δ4 products by hydroxysteroid dehydrogenases isoform 3B2, yielding 4-androstenedione (A4) and testosterone, respectively.
A critical metabolic distinction is that conventional DHEA (5-DHEA) is sulfated rapidly by liver sulfotransferases to DHEA-S upon oral ingestion. DHEA is rapidly metabolized by liver enzymes referred to as sulfotransferases. These sulfotransferases rapidly convert much of the supplementary DHEA into DHEA sulfate, which is quickly excreted from the body and is not considered effective as an anti-aging or muscle-building compound. DHEA sulfate does not restore the balance of adrenal steroids, and as a result, frequent and larger doses of DHEA must be taken. The proponents of 4-DHEA argue, on theoretical grounds, that the Δ4 double bond position makes the molecule a less efficient substrate for sulfation, potentially yielding more direct conversion toward the androgen pathway — though this specific claim has not been validated in peer-reviewed pharmacokinetic studies specifically examining 4-DHEA in humans.
Oral bioavailability of prohormone steroids in this class is generally recognized to be low without formulation intervention. 4-Androstenolone, like other prohormones, only converts 1.5–4% of the hormone orally ingested without enhanced delivery. Manufacturers have responded by developing liposomal and cyclodextrin-based delivery technologies. The specific claim that these technologies achieve near-complete bioavailability comes from manufacturer literature and has not been independently validated in peer-reviewed pharmacokinetic studies for 4-DHEA.
The compound is a naturally occurring prohormone of androgens and estrogens and hence is an agonist of the androgen and estrogen receptors, the respective biological targets of androgens like testosterone and estrogens like estradiol — primarily via its downstream conversion products rather than through direct high-affinity receptor binding of 4-DHEA itself.
Regarding the parent compound class (DHEA family), despite intense effort by scientists to elucidate the multifunction of DHEA, its mechanism of action is still elusive. Most of its physiological actions have been attributed to its conversion to either androgens or estrogens. Depending on the tissue, DHEA can be metabolized to 4-androstenedione, 5α-androstenedione, testosterone, estrogen, and other biologically active steroids.
DHEA also has a variety of potential biological effects in its own right, binding to an array of nuclear and cell surface receptors, and acting as a neurosteroid and modulator of neurotrophic factor receptors. In 2011, the discovery was made that DHEA, as well as its sulfate ester DHEA-S, directly bind to and activate TrkA and p75NTR — receptors of neurotrophins like nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) — with high affinity. DHEA was subsequently also found to bind to TrkB and TrkC with high affinity, though it only activated TrkC and not TrkB. DHEA and DHEA-S bound to these receptors with affinities in the low nanomolar range (around 5 nM), which were nonetheless approximately two orders of magnitude lower relative to highly potent polypeptide neurotrophins like NGF (0.01–0.1 nM). Whether these receptor interactions extend to 4-DHEA specifically has not been established.
The exact mechanism of action of DHEA remains uncertain, with some evidence suggesting it has pleiotropic effects. As DHEA has minor steroidogenic activity, it acts predominantly by conversion to androgens and estrogens in peripheral target tissues.
One of the main characteristics of DHEA is its age-dependent pattern of secretion: its production begins during fetal life, reaches the highest serum levels between the ages of 20 and 30, and then steadily declines at a rate of 2% to 5% per year, resulting in a decline of up to 80% in old age. Significant clinical interest in this age-dependent decrease exists because it has been shown to be associated with physical health.
The decline in DHEA/DHEAS levels with age has been linked to the onset of many age-related chronic diseases and symptoms, such as osteopenia, sarcopenia, atherosclerosis, immunosenescence, and cognitive and mood impairment. This has led to the hypothesis that restoring youthful DHEA/DHEAS levels through supplementation may provide health benefits in middle to older adults.
DHEA and DHEAS start increasing in boys and girls around the age of six to eight years — a process known as adrenarche — and peak in the second to third decade of life. Thereafter there is a progressive decline by around 2%–5% each year with advancing age, such that levels decrease by 80%–90% in the eighth to ninth decade of life.
It should be noted explicitly that the clinical studies examining the health consequences of DHEA decline, and the supplementation trials designed to reverse it, relate to conventional DHEA (5-DHEA). No published human clinical trials specifically using 4-DHEA as the intervention have been identified in the peer-reviewed literature.
Important methodological caveat: Peer-reviewed clinical trials involving 4-DHEA as the specific test article are absent from the published literature as of the time of this writing. The body of clinical research summarized below pertains to 5-DHEA (prasterone/androstenolone), the conventional isomer that has been the subject of randomized controlled trials, systematic reviews, and regulatory review. This evidence is presented here because 4-DHEA is sold on the premise of similar or superior conversion to testosterone and androgenic downstream effects. Where relevant, limitations on extrapolating 5-DHEA data to 4-DHEA are noted.
DHEA has been aggressively sold as a dietary supplement to boost testosterone levels, although the impact of DHEA supplementation on testosterone levels has not been fully established. Systematic reviews and meta-analyses of RCTs have been performed to investigate the effect of oral DHEA supplementation on testosterone levels.
Testosterone was significantly more increased in the subgroup who received DHEA supplementation dosages of greater than 50 mg/day. DHEA increased testosterone levels in all subgroups, but the magnitude of increment was higher in females compared to men.
One meta-analysis including 21 studies, comprising 17 trial arms assessing estradiol and 20 assessing testosterone, found that DHEA supplementation significantly increased estradiol (WMD: 7.86 pg/mL; 95% CI 6.33–9.40) and testosterone levels. This meta-analysis found that DHEA supplementation at doses of 50 mg/day or higher significantly increased testosterone levels, and in participants aged 60 years or older, significantly elevated estradiol levels.
Evidence strength: Moderate for an effect on circulating testosterone levels in older adults using 5-DHEA at ≥50 mg/day. The magnitude of the effect varies substantially across populations and is modest in absolute terms. No controlled human trials exist for 4-DHEA specifically.
Testosterone concentrations decrease with age and contribute to reduced muscle mass and bone density, impaired hair growth, and sexual dysfunction. Despite the fact that numerous clinical studies have evaluated the positive effects of DHEA supplementation on testosterone concentrations and body mass index (BMI), more evidence is needed to certify that DHEA is a BMI-reducing agent in the elderly.
DHEA is a weak androgen that needs conversion to more potent testosterone, and the assumption is that athletes expect a significant increase in circulating testosterone through exogenous DHEA administration, with a subsequent improvement in performance. The literature on the ergogenic effects of DHEA intake is nevertheless very scant, and to our knowledge none of the studies has presented evidence that DHEA use improves athletic performance.
Ergogenic and anabolic effects related to 4-androstenedione intake have not been substantiated. This conclusion from FDA-referenced literature on 4-androstenedione — the primary metabolite of 4-DHEA — further underscores the absence of confirmed performance-enhancing effects in the conversion pathway relevant to 4-DHEA.
Evidence strength: Weak to absent for direct ergogenic or anabolic effects of 4-DHEA. The mechanistic rationale (conversion to testosterone) is biochemically plausible, but no controlled human performance trials exist for 4-DHEA. Extrapolation from the 5-DHEA literature does not show robust evidence for muscle mass or performance improvement in healthy subjects.
Particularly in postmenopausal women, DHEA has shown potential benefits in treating genitourinary syndrome of menopause (GSM), including improved vaginal health, lubrication, and sexual function.
At present, the clinical use of dehydroepiandrosterone is limited; approved uses include Intrarosa® (prasterone) 6.5 mg vaginal suppositories for the treatment of vaginal atrophy and dyspareunia, while DHEA synthetic derivatives have investigational status for various other diseases.
One registered clinical trial was designed to determine the role of testosterone and DHEA in enhancing sexual interest and sexual performance, with 120 men with a diagnosis of erectile dysfunction randomized to one of three arms: DHEA (50 mg), testosterone (80 mg), or placebo. No equivalent trial has been published for 4-DHEA.
Evidence strength: Moderate for intravaginal 5-DHEA (prasterone) in menopausal GSM, where an FDA-approved product exists. Oral DHEA for sexual function has mixed and modest evidence. No evidence exists for 4-DHEA specifically in sexual function outcomes.
As age-related decline in androgens and estrogens is said to contribute to the loss of muscle mass and bone mineral density in older adults, DHEA has been suggested as a potential agent for minimizing these losses.
The position statement on supplementation with DHEA in pre- and postmenopausal females (2020) concluded that, based on current evidence, DHEA supplementation is effective in postmenopausal females with low BMD and/or osteoporosis. The dosing recommendation in that statement was 25 mg/day orally titrated to 50 mg/day, then to 100 mg/day.
Evidence strength: Modest for conventional oral DHEA's effect on bone mineral density in postmenopausal women; some position statements have endorsed it in specific populations. No data specific to 4-DHEA and bone outcomes exist.
The strongest evidence for the use of DHEA in a disease state comes from the literature of DHEA in adrenal insufficiency. A small study of only women with primary adrenal insufficiency established that 50 mg/day of DHEA restored levels back into the normal range, whereas 200 mg/day resulted in supraphysiological levels of androgens. Twenty-four women with adrenal insufficiency were studied in a randomized, double-blinded, placebo-controlled, cross-over trial.
There is little clinical use of DHEA — except in the case of pathologic adrenal failure, in which replacement is associated with improvements.
Evidence strength: Moderate for 5-DHEA in adrenal insufficiency, which represents the most robustly supported clinical indication. Not applicable to 4-DHEA as a specific intervention.
In a small, six-week study, researchers from the National Institute of Mental Health found that treatment with DHEA supplements helped relieve mild to moderate depression in some middle-aged people.
Dehydroepiandrosterone (DHEA) and its sulfate ester form DHEAS are multifunctional steroid hormones primarily produced in the adrenal cortex, with additional synthesis in peripheral tissues. DHEA/DHEAS serve as precursors to sex steroids and exhibit neuroprotective, anti-inflammatory, and immune-modulating effects.
Since DHEA can increase testosterone and estrogen levels, its supplementation shows some promise for easing mild to moderate depression, but more research is needed. For other conditions, there is little evidence to support claims that DHEA has value in treating conditions such as fibromyalgia, addressing issues with memory or muscle strength, or enhancing and stimulating the immune system.
Evidence strength: Preliminary and largely insufficient for cognitive or mood outcomes with oral DHEA supplementation. No evidence exists for 4-DHEA in any neurological or psychiatric endpoint.
In men with type 2 diabetes, after adjustment for potential confounders, the risk of coronary heart disease (CHD) decreased with increasing serum DHEA level (odds ratio = 0.38 for Q4 vs. Q1; 95% CI = 0.16–0.90; p = 0.037 for trend). When considered as a continuous variable, this association remained significant in the fully adjusted model (OR = 0.59, 95% CI = 0.40–0.87, p < 0.05).
This association is observational, and causality is not established. No intervention trial using DHEA or 4-DHEA specifically targeting cardiovascular outcomes with confirmed benefit exists. The literature concerning the relationship between DHEA and aging, obesity, cardiovascular disease, cancer, depression, immune function, and adrenal insufficiency has been extensively reviewed, though much remains inconclusive.
Evidence strength: Observational/associational only for cardiovascular endpoints with 5-DHEA. No interventional data and no data for 4-DHEA.
Among strategies proposed to improve fertility in women approaching 40, increasing attention has been aimed at dehydroepiandrosterone (DHEA) supplementation. DHEA is an essential prohormone in ovarian follicular steroidogenesis. Because of its potential to slow down and reverse the effects of aging, DHEA has been proposed as a novel treatment to improve the fertility rate in women with diminished ovarian reserve (DOR).
It has been suggested that DHEA supplementation may increase the number of available follicles in poor ovarian responders through an increased serum level of insulin-like growth factor, increased follicular response to follicle stimulating hormone (FSH), and improved quality of oocytes. However, the efficacy of DHEA pre-treatment has been controversial, with partial to low clinical evidence being observed.
In the absence of randomized studies, DHEA cannot be recommended as a routine protocol in advanced reproductive age.
Evidence strength: Mixed and preliminary for 5-DHEA in reproductive medicine; some retrospective and small prospective data suggest benefit in poor ovarian responders, but robust RCT evidence is lacking. No data exist for 4-DHEA in reproductive contexts.
Based on its known conversion pathway to testosterone and estradiol, 4-DHEA is associated — at least mechanistically — with the following body systems. The strength of evidence for actual clinical benefit in any of these areas via 4-DHEA specifically is absent from the peer-reviewed literature:
No published peer-reviewed pharmacokinetic or clinical dose-ranging studies specifically for 4-DHEA in humans have been identified. The following dosing information derives from commercial product labeling and, where available, from general DHEA literature:
Because 4-DHEA requires a two-step enzymatic conversion to testosterone with substantial first-pass losses, commercially marketed doses of 50–300 mg per day are common in product literature, though none of these dose levels have been validated in controlled pharmacokinetic studies for 4-DHEA itself.
Some side effects occur because DHEA can raise testosterone and estrogen levels in the body. Experts warn that we do not know enough about the long-term effects of increased hormone levels.
Side effects of DHEA-class supplementation in women include symptoms of masculinization like oily skin, acne, increased hair growth, voice changes, and increased sexual desire, as well as headaches and insomnia. In men, the aromatization of downstream testosterone to estradiol can cause gynecomastia and fluid retention.
Androstenedione — the primary metabolite of 4-DHEA — has been found to possess some estrogenic activity, similarly to other DHEA metabolites. Short-term administration of 4-androstenedione has been associated with increased serum testosterone and estrogen levels in men and women.
Use of DHEA-class supplements might raise levels of androgen and have a steroid effect. Taking high doses or using it for a long time might raise the risk of hormone-sensitive cancers, such as prostate and breast cancers.
Androstenedione — the downstream metabolite of 4-DHEA — is the steroid hormone used by the body to make testosterone and estrogen. Taking androstenedione appears to increase estrogen levels. Men and women with hormone-sensitive conditions should therefore avoid this class of compound. Some of these conditions include breast, uterine, ovarian, and prostate cancer; endometriosis; and uterine fibroids.
DHEA is a weak androgen, and adrenal androgens are associated with an increased risk of cancer, especially of the breast and prostate. Until rigorous laboratory and clinical studies have been conducted, use of DHEA-S in cancer prevention cannot be supported. The relevance of effects of DHEA in rodent models of cancer is unclear. Epidemiological data are inconclusive regarding the role of DHEA and DHEA-S in cancer.
There is some concern that androstenedione — the primary metabolite of 4-DHEA — might harm the liver. 4-DHEA itself is described as a non-methylated prohormone, a structural feature associated with lower direct hepatotoxicity compared to 17-alpha-alkylated anabolic steroids. However, no controlled hepatotoxicity studies for 4-DHEA have been published, and the general risks associated with prohormone supplementation and liver function cannot be ruled out based on available data.
Because 4-DHEA raises downstream testosterone levels through its conversion pathway, exogenous administration has the theoretical potential to suppress the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback. This concern applies to all testosterone-boosting agents, including conventional DHEA. Supplement product labels for 4-DHEA typically specify cycled use (4–8 weeks) followed by post-cycle therapy, reflecting industry awareness of HPG suppression, though the magnitude of suppression specifically attributable to 4-DHEA at typical supplement doses has not been quantified in clinical research.
Because 4-DHEA converts to testosterone and estradiol, extra care is warranted when taking drugs that affect hormones, including estrogen, progesterone, testosterone, anastrozole, exemestane, fulvestrant, letrozole, or tamoxifen. Co-administration with hormone-modulating drugs may produce additive hormonal effects or alter the pharmacodynamics of the co-administered medication.
DHEA figures on the World Anti-Doping Agency (WADA) list of prohibited substances in sport, and its use is prohibited both in competition and out of competition. DHEA, as "prasterone," is included in the pharmacological class S1 "Anabolic Agents" as Anabolic Androgenic Steroids (AAS) in the subclass of "Endogenous AAS when administered exogenously."
Although its use is prohibited under the World Anti-Doping Code and the National Collegiate Athletic Association, several high-profile athletes have tested positive for DHEA. The International Olympic Committee also prohibits the use of DHEA in sports, and the NCAA includes DHEA in its list of banned substances. As a positional isomer of prasterone with the same molecular formula, 4-DHEA and its metabolites are similarly subject to doping controls. For endogenous hormones such as testosterone or DHEA, it is mandatory in doping control to determine the origin of the steroid using isotope ratio mass spectrometry techniques.
DHEA-class supplements should not be taken during pregnancy or while breastfeeding, and children should not use them. Commercial 4-DHEA products are labeled for use by adult men only, and contraindicated in individuals under 21 years of age.
Studies have argued against the use of DHEA as a cure-all elixir, and the lack of long-term safety data does not justify the use of DHEA in healthy elderly individuals. We need more research to know whether DHEA supplements are safe. This uncertainty is compounded for 4-DHEA, which has received far less scientific scrutiny than conventional 5-DHEA.
4-Dehydroepiandrosterone occupies a scientifically unusual position: it is a genuine endogenous steroid isomer with a plausible biochemical mechanism as a testosterone precursor, yet it essentially lacks a clinical trial evidence base of its own. The substantial research corpus on 5-DHEA (prasterone) cannot be straightforwardly extrapolated to 4-DHEA because the two isomers differ in double bond position, sulfation susceptibility, conversion pathway efficiency, and potentially in receptor activity. While some provocative data suggest that DHEA plays a role in many physiological functions, few data support its use in the clinical setting. By marketing DHEA as a nutritional supplement in the US, companies can bypass the rigorous clinical trials required for approval for medicinal use of any substance.
The compound's commercial profile is that of a post-prohormone-ban supplement, positioned in the bodybuilding and performance market on the basis of its structural relationship to testosterone-precursor steroids. Its classification as a dietary supplement under DSHEA makes it legally available over the counter in the United States, while it remains banned in competitive sports under WADA rules. Researchers, clinicians, and regulatory bodies have not published independent assessments of 4-DHEA as a distinct entity separate from the broader DHEA/prohormone literature.
Health conditions that 4-DHEA may help support.
Body systems that 4-DHEA may help support.
Go back